Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.

Wen-Hsuan Hou Kai-Cheng Chang Chung-Yi Li Huang-Tz Ou

Published in: British journal of clinical pharmacology (2018)

The results of this study supported the premise that DPP-4i usage is associated with a reduced risk of all-cause fractures and upper extremity fractures in patients with type 2 diabetes.

Keyphrases

hip fracture